Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Moodys
Johnson and Johnson
AstraZeneca
Boehringer Ingelheim

Last Updated: May 28, 2022

TYGACIL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Tygacil, and when can generic versions of Tygacil launch?

Tygacil is a drug marketed by Pf Prism Cv and is included in one NDA. There are six patents protecting this drug.

This drug has sixty-two patent family members in twenty-nine countries.

The generic ingredient in TYGACIL is tigecycline. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the tigecycline profile page.

Drug patent expirations by year for TYGACIL
Drug Prices for TYGACIL

See drug prices for TYGACIL

Recent Clinical Trials for TYGACIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Zhujiang Hospital
PfizerPhase 4
Manjunath Prakash PaiPhase 4

See all TYGACIL clinical trials

Pharmacology for TYGACIL

US Patents and Regulatory Information for TYGACIL

TYGACIL is protected by six US patents.

Patents protecting TYGACIL

Tigecycline compositions and methods of preparation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Tigecycline compositions and methods of preparation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Crystalline solid forms of tigecycline and methods of preparing same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Tigecycline compositions and methods of preparation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Tigecycline compositions and methods of preparation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Tigecycline compositions and methods of preparation
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 AP RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 AP RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 AP RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 AP RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 AP RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 AP RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TYGACIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 See Plans and Pricing See Plans and Pricing
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 See Plans and Pricing See Plans and Pricing
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 See Plans and Pricing See Plans and Pricing
Pf Prism Cv TYGACIL tigecycline POWDER;INTRAVENOUS 021821-001 Jun 15, 2005 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TYGACIL

See the table below for patents covering TYGACIL around the world.

Country Patent Number Title Estimated Expiration
New Zealand 244585 9-SUBSTITUTED-AMINO TETRACYCLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS See Plans and Pricing
Argentina 057649 FORMAS SOLIDAS CRISTALINAS DE TIGECICLINA Y METODOS PARA PREPARAR LAS MISMAS See Plans and Pricing
Taiwan 200720232 Crystalline solid forms of tigecycline and methods of preparing same See Plans and Pricing
Ecuador SP078055 FORMAS SÓLIDAS CRISTALINAS DE TIGECICLINA Y MÉTODOS PARA PREPARAR LAS MISMAS See Plans and Pricing
Russian Federation 2478612 КРИСТАЛЛИЧЕСКИЕ ФОРМЫ ТАЙГЕЦИКЛИНА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ (CRYSTALLINE FORMS OF TIGECYCLINE AND METHOD FOR PREPARING THEM) See Plans and Pricing
Denmark 1858488 See Plans and Pricing
Guatemala 200600112 COMPOSICIIONES DE TIGECICLINA Y METODOS DE PREPARACION See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for TYGACIL

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0536515 SPC030/2006 Ireland See Plans and Pricing SPC030/2006: 20071025, EXPIRES: 20170820
0536515 0690028-6 Sweden See Plans and Pricing PRODUCT NAME: TIGECYKLIN
0536515 C300244 Netherlands See Plans and Pricing PRODUCT: TIGECYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX, IN HET BIJZONDER TIGECYCLINE; FIRST REGISTRATION, DATE: EU/1/06/336/001, 20060424
0536515 91279 Luxembourg See Plans and Pricing 91279, EXPIRES: 20170821
0536515 34/2006 Austria See Plans and Pricing PRODUCT NAME: TIGECYCLIN UND DIE PHARMAKOLOGISCH UNBEDENKLICHEN ORGANISCHEN UND ANORGANISCHEN SALZE DAVON; REGISTRATION NO/DATE: EU/1/06/336/001 20060424
0536515 2006/030 Ireland See Plans and Pricing PRODUCT NAME: TIGECYCLINE OR A PHARMACOLOGICALLY ACCEPTABLE ORGANIC OR INORGANIC SALT OR METAL COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/06/336/001 20060424
0536515 C00536515/01 Switzerland See Plans and Pricing FORMER OWNER: WYETH HOLDINGS CORPORATION, US
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Baxter
AstraZeneca
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.